Wojcicki attempted to take 23andMe private, proposing an official offer to the board of directors in late July. However ...
Back in September, all of 23andMe's independent directors also resigned from its board — a rare move that followed ...
No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...
Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...
DNA-testing company 23andMe said on Monday that it was firing roughly ... The company announced two weeks ago that it had ...
In another blow to the company, seven of 23andMe’s eight-strong board resigned in September. The firm's independent ...
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...